A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicenter, retrospective cohort analysis comparing 321 CL...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Mato, Anthony R., Roeker, Lindsey E., Eyre, Toby A., Nabhan, Chadi, Lamanna, Nicole, Hill, Brian T., Brander, Danielle M., Barr, Paul M., Lansigan, Frederick, Cheson, Bruce D., Singavi, Arun K., Yazdy, Maryam Sarraf, Shah, Nirav N., Allan, John N., Bhavsar, Erica B., Rhodes, Joanna, Kennard, Kaitlin, Schuster, Stephen J., Williams, AnnaLynn M., Skarbnik, Alan P., Goy, Andre H., Goodfriend, Julie M., Dorsey, Colleen, Coombs, Catherine C., Tuncer, Hande, Ujjani, Chaitra S., Jacobs, Ryan, Winter, Allison M., Pagel, John M., Bailey, Neil, Schuh, Anna, Shadman, Mazyar, Sitlinger, Andrea, Weissbrot, Hanna, Muralikrishnan, Sivraj, Zelenetz, Andrew, Kirkwood, Amy A., Fox, Christopher P.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2019
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538868/
https://ncbi.nlm.nih.gov/pubmed/31101647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000180
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky